Cardiff Oncology Company Top Insiders
| CRDF Stock | USD 2.02 0.04 1.94% |
Cardiff Oncology's insiders are aggressively buying. The analysis of the overall insider sentiment regarding Cardiff Oncology suggests that almost all insiders are extremely bullish. Cardiff Oncology employs about 32 people. The company is managed by 9 executives with a total tenure of roughly 75 years, averaging almost 8.0 years of service per executive, having 3.56 employees per reported executive.
Insider Sentiment 100
Aggressively Buying
Selling | Buying |
Latest Trades
| 2025-07-30 | Gary W Pace | Acquired 15000 @ 2.45 | View | ||
| 2024-12-11 | Gary W Pace | Acquired 350115 @ 2.6 | View |
Monitoring Cardiff Oncology's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cardiff Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in services. Cardiff Oncology's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Cardiff Oncology's future performance. Based on our forecasts, it is anticipated that Cardiff will maintain a workforce of roughly 30 employees by December 2025.Cardiff Oncology Management Team Effectiveness
The company has return on total asset (ROA) of (0.5299) % which means that it has lost $0.5299 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0271) %, meaning that it created substantial loss on money invested by shareholders. Cardiff Oncology's management efficiency ratios could be used to measure how well Cardiff Oncology manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.49. The Cardiff Oncology's current Return On Capital Employed is estimated to increase to -0.55. At this time, Cardiff Oncology's Net Tangible Assets are most likely to increase significantly in the upcoming years.The Cardiff Oncology's current Common Stock Shares Outstanding is estimated to increase to about 50 M, while Net Loss is projected to decrease to (36.6 M).
Cardiff Oncology Workforce Comparison
Cardiff Oncology is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 698. Cardiff Oncology holds roughly 32.0 in number of employees claiming about 5% of equities under Health Care industry.
Cardiff Oncology Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Cardiff Oncology insiders, such as employees or executives, is commonly permitted as long as it does not rely on Cardiff Oncology's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Cardiff Oncology insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2023-03-01 | 4.0 | 4 | 1 | 972,144 | 425,000 |
| 2022-03-01 | 18.0 | 18 | 1 | 1,741,920 | 275,088 |
| 2021-03-01 | 3.75 | 15 | 4 | 29,025 | 474.00 |
| 2020-12-01 | 0.5 | 1 | 2 | 35,321 | 70,642 |
| 2020-06-01 | 2.375 | 19 | 8 | 1,197,897 | 237,231 |
| 2020-03-01 | 0.5 | 2 | 4 | 1,511 | 2,179 |
| 2019-12-01 | 0.5 | 1 | 2 | 1,250 | 1,716 |
| 2019-09-01 | 0.5 | 1 | 2 | 1,250 | 1,711 |
| 2019-06-01 | 3.5 | 7 | 2 | 612,619 | 1,709 |
| 2019-03-01 | 0.5 | 2 | 4 | 9,063 | 12,796 |
| 2018-12-01 | 0.5 | 1 | 2 | 7,500 | 10,231 |
| 2018-03-01 | 1.15 | 23 | 20 | 2,205,779 | 665,866 |
| 2017-09-01 | 0.9 | 9 | 10 | 1,212,078 | 141,054 |
| 2017-03-01 | 11.0 | 22 | 2 | 606,690 | 73,968 |
| 2016-12-01 | 5.0 | 5 | 1 | 34,716 | 322,472 |
| 2016-06-01 | 1.0 | 3 | 3 | 125,639 | 931,667 |
| 2015-09-01 | 0.5 | 4 | 8 | 185,000 | 1,075,000 |
| 2014-12-01 | 7.0 | 7 | 1 | 311,668 | 24,000 |
| 2014-03-01 | 6.0 | 6 | 1 | 111,537 | 8,333 |
| 2013-12-01 | 2.0 | 2 | 1 | 100,000 | 8,333 |
| 2013-09-01 | 0.5 | 1 | 2 | 90,000 | 19,200 |
| 2013-03-01 | 6.0 | 6 | 1 | 77,094 | 8,333 |
| 2012-03-01 | 0.4615 | 6 | 13 | 270,000 | 6,892,247 |
Cardiff Oncology Notable Stakeholders
A Cardiff Oncology stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Cardiff Oncology often face trade-offs trying to please all of them. Cardiff Oncology's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Cardiff Oncology's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Elizabeth Anderson | VP Administration | Profile | |
| James Levine | Chief Officer | Profile | |
| Mark Erlander | CEO Director | Profile | |
| Vicki Kelemen | Chief Officer | Profile | |
| Tod Smeal | Chief Officer | Profile | |
| Roger MD | Chief Officer | Profile | |
| Brigitte Lindsay | Senior Finance | Profile | |
| MD FACP | Chief Officer | Profile | |
| Charles RPh | Senior Affairs | Profile |
About Cardiff Oncology Management Performance
The success or failure of an entity such as Cardiff Oncology often depends on how effective the management is. Cardiff Oncology management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Cardiff management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Cardiff management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.47) | (0.49) | |
| Return On Capital Employed | (0.58) | (0.55) | |
| Return On Assets | (0.47) | (0.49) | |
| Return On Equity | (0.55) | (0.58) |
Cardiff Oncology Workforce Analysis
Traditionally, organizations such as Cardiff Oncology use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Cardiff Oncology within its industry.Cardiff Oncology Manpower Efficiency
Return on Cardiff Oncology Manpower
| Revenue Per Employee | 21.3K | |
| Revenue Per Executive | 75.9K | |
| Net Loss Per Employee | 1.4M | |
| Net Loss Per Executive | 5M | |
| Working Capital Per Employee | 2.6M | |
| Working Capital Per Executive | 9.1M |
Complementary Tools for Cardiff Stock analysis
When running Cardiff Oncology's price analysis, check to measure Cardiff Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cardiff Oncology is operating at the current time. Most of Cardiff Oncology's value examination focuses on studying past and present price action to predict the probability of Cardiff Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cardiff Oncology's price. Additionally, you may evaluate how the addition of Cardiff Oncology to your portfolios can decrease your overall portfolio volatility.
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |